Refer refractory afib for catheter ablation
In this unblinded trial, 167 patients with recurrent symptomatic afib despite anti-arrythmic therapy were randomized to catheter ablation or another anti-arrythmic therapy. At 9 months, 66% of the catheter group remained free of recurrent afib, compared to only 16% of the anti-arrythmic group. Treatment related major adverse effects occurred in 5% of the catheter group compared to 9% of the anti-arrythmic group at 30 days. Catheter ablation is a reasonable treatment strategy for patients with symptomatic paroxysmal afib refractory to medical therapy (abstract)
